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Antisense inhibition of hypertension: A new strategy for renin.angio-
tensin candidate genes. There are several ways of experimentally studying
the influence of candidate genes on hypertension. The approach proposed
here is antisense inhibition with antisense oligodeoxynucleotides (AS-
ODNs) constructed to the 5' region of known sequences of angiotensino-
gen mRNA and angiotensin tI type-i receptor mRNA. The AS-ODNs
were applied in vivo and in vitro. In vivo, direct injection of 50 jig of
AS-ODN into the lateral ventricles of SHR reduced hypertension signif-
icantly (P < 0.01). There was no effect of AS-ODN i.c.v. in normotensive
WKY rats. The phosphorothiated AS-ODN to the AT1 receptor mRNA
also produced a long-lasting decrease in blood pressure in SHR (7 days).
After AS-ODN treatment AT1 receptors were reduced in the PVN and
anterior third ventricle area and Ang II levels were reduced in the
brainstem. The results show the in vivo feasibility of using antisense
inhibition of renin-angiotensin mRNA to reduce hypertension.
The renin-angiotensin system has components that appear to be
candidate genes for hypertension [1]. There are several ways of
experimentally tackling the problem of genetic control of hyper-
tension. These include: breeding, studies with backcross breeding
to show gene linkage between hypertension and candidate genes,
transgenic techniques with the insertion of a candidate gene, and
gene knockout. These techniques are currently being used and
have advantages and disadvantages in isolating linkage to hyper-
tension. For example, Kimura et al [2] have shown that the
angiotensinogen gene inserted in transgenic mice is associated
with hypertension, particularly with the expression of the gene in
brain tissue. Previous work indicated that brain angiotensin is an
important factor in the hypertension of the genetic strain of
spontaneously hypertensive rats (SHR) [3—61. Cost and lack of
experience have prevented us from undertaking genetic breeding
studies to breed out hypertension and measures of brain RAS
components. A more cost effective approach is to inhibit proteins
with antisense oligonucleotides to specific gene expression [7].
Recently we have begun applying this approach to inhibit the
mRNA expression of angiotensinogen and AT1 receptors by
antisense inhibition, The antisense approach is based on observa-
tions that bacteria can regulate gene replication and transcription
by producing small complementary antisense RNA molecules.
Many reports have followed describing the down-regulation of
translation in vitro of various oncogenes by both DNA and RNA
antisense techniques [7]. Antisense has the advantage of being as
specific as a genetic approach, and yet as available as a pharma-
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cological approach. We have recently demonstrated that in vivo
delivery of antisense oligodeoxynucleotides (AS-ODN) to com-
ponents of the renin-angiotensin system in the brain can signifi-
cantly reduce high blood pressure in the SHR [8).
Antisense ODNs are constructed to the base sequence of the 5'
coding region of the known sequence of candidate gene mole-
cules. The initial constructs were phosphodiester linked ODNs.
These were effective even though they were unmodified. Phos-
phorothioated ODNs were also produced as they are considered
to be more stable because of the modified phosphate groups in the
backbone of the molecule and have longer-lasting effects than the
unmodified antisense.
Methods
Adult male SHR and WKY rats (250 to 300 g) supplied by
Harlan, Inc. were cannulated in the right brain ventricle with a 23
gauge stainless steel cannula. Five days after surgery the rats were
catheterized in the left common carotid artery. All experimental
procedures were approved by the University of Florida Animal
Welfare Committee.
Antisense and scrambled ODNs were constructed to target the
angiotensinogen gene [9] (antisense: 5'-CCGTGGGAGTCAT-
CACGG-3', sense: 5 '-CCGTGATGACTCCCACGG-3', scram-
bled: 5'-CAGGGATCTCTGGCGGAC-3'.) The AS sequence
targeted to the AT1 receptor mRNA [10] was: 5'-TAACTGTG-
GCTGCAA-3'. The sense sequence was: 5'-TGGCAGGCA-
CAGTIA-3'.
Groups of six rats received three i.c.v. injections at 12 hour
intervals with 50 p.g of angiotensinogen AS, 5, or SC ODN or a
vehicle of 5 p.1 isotonic saline. Systolic blood pressure was
measured either via the catheter or in longer term experiments by
tailcuff blood pressure measurement.
Northern blots of angiotensinogen mRNA were analyzed in
SHR and WKY after ODN treatment. Tissue RNA was extracted
by the method of Chomczynsky and Sacchi [11]. Tissue samples
from chronically treated rats were taken two hours after final
treatment.
Kidney and brain tissue and plasma samples were obtained two
hours after final ODN injection. The samples were frozen and
stored for later extraction and radioimmunoassay procedures [12].
To measure the effect of AS-ODN targeted to the AT1 receptor
mRNA, autoradiography was carried out on frozen sections cut at
20 p.m thickness at — 20°C. The sections were incubated with 500
M '251-Sar-Ile-Ang II for two hours in the presence of absence of
1 p.m Ang II. Sections were washed in 10 m sodium biphosphate
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Fig. 1. Change in systolic blood pressure (SBP) in chronically treated SHR
and WKY rats. Intracerebroventricular administration of three doses of 50
pg (10 rg/j.d) angiotensinogen antisense (AS), sense (S), scrambled (Sc)
ODN or 5 i1 isotonic saline (C). Systolic blood pressure was reduced from
baseline levels in SHR's treated with AS-ODN 35.5 6.2 mm Hg, N = 6,
< 0.01.
buffer and dried. Autoradiograms were generated by apposition of
slide mounted tissues with x-ray film (Hyperfilm-3H, Amersham)
for three days. Densitometric analysis was carried out with Image
Systems (MCID Ml software).
All values were expressed as means SEM. Statistical analysis
was performed by ANOVA with Duncan multiple range test for
individual comparisons.
Results
A highly significant decrease in blood pressure was observed in
the chronically treated SHR rats (Fig. 1A). Systolic blood pressure
was reduced from baseline levels after AS-ODN treatment by 35.5
6.2 mm Hg (N 6, P < 0.01). The controls, sense vehicle and
scrambled, produced no significant effect on the blood pressures.
In the normotensive rat (WKY), AS, S and vehicle had no effect
on the blood pressure (Fig. 1B). The decrease in blood pressure
began two hours after the first dose of 50 ig (10 g,/.d) but the
maximum effect was seen two hours after the last of the three
doses given at 12 hour intervals. The treatment normalized the
high blood pressure to levels below 150 mm Hg in SHR.
The effect of the AS-ODN was to reduce Ang II levels in the
brainstem, compared to control groups of S, Sc and saline treated
SHR (59 6.1 vs. 71 6.4 pglg tissue, P < 0.05, N = 6). No
change in Ang II was observed in the kidney or in the plasma Ang
II levels in SHR after treatment.
The effect of AS inhibition of the AT1 receptor mRNA was a
significant reduction in blood pressure. Rats injected with the
receptor AS-ODN (50 j.tg in 5 M1 saline) received one dose. This
resulted in a significant fall in mean arterial pressure of 27 8
mm Hg (P < 0.01) in SHR (Fig. 2). Neither control nor sense
ODN produced a decrease in blood pressure. The reduced blood
pressure lasted for seven days. Autoradiography shows a signifi-
cant decrease in 1251-Sar-Ile Ang II binding in the PVN and in the
AV3V region, particularly the organum vasculosum of the lamina
terminalis (OVLT). Northern blot analysis of mRNA for Ao
showed no change in mRNA levels between AS and control
treated groups or between SHR and WKY strains.
Discussion
The experiments illustrate the viability of antisense inhibition in
vivo for reduction of blood pressure in genetically hypertensive
rats. Both antisense to angiotensinogen mRNA and to AT1
receptor mRNA were successful in reducing blood pressure [8].
Reduction in blood pressure was correlated to an inhibition of
Ang II synthesis and AT1 receptor binding, respectively. Further
experiments in our laboratory are being carried out on the effects
of AS on angiotensinogen levels in brain, kidney and liver after
angiotensinogen mRNA AS-ODN treatment and on receptor
binding, in vitro. Physiological mechanisms associated with an
overactive brain angiotensin, are also inhibited by the AS-ODN.
These include: Ang II induced thirst and Ang II induced vaso-
pressin release.
There are several practical issues that have to be considered in
order to use AS-ODNs efficiently. These include a method of
delivery, the stability of the ODNs in tissue and their ability to be
taken up across the plasma membrane and delivered to the
Phillips et al: Antisense inhibition of RAS 1555
E
E
0..
Fig. 2. Decrease in mean arterial pressure (MAP) in SHR 24 hours after
ic. v. injection of 50 pg antisense ODN to the AT1 receptor mRNA. Symbols
are: (EJ) pre-treatment; ( ) 24hours. For blood pressure measurements,
the carotid artery was catheterized. Baseline blood pressure data was
recorded one hour before injection. N = 6, control; N = 7, sense; N 7,
antisense; P < 0.01.
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mRNA for binding. The mechanisms by which antisense ODNs
inhibit gene expression and the site of action in the nucleus also
require further investigation. In vitro studies in our laboratory
with FITC labeled AS-ODN have demonstrated the uptake of the
ODN into hepatoma cells. The intracellular location of the
labeled AS-ODN is revealed by confocal mincroscopy. For deliv-
ery of AS-DNA to tissues we are constructing a viral vector in a
Sendai viral envelope. This method should integrate the AS-DNA
into the chromosome and produce long-lasting inhibition of the
angiotensinogen gene or AT1 receptor gene. Our present results
do show that sufficient ODN uptake occurs in vivo to provide
inhibition of blood pressure which appears to be related to the
inhibition of angiotensinogen gene or AT1 receptor gene expres-
sion. The fact that AS treatment has no apparent effect on mRNA
level is consistent with the proposed mechanism of action of AS
molecules being at the translational level. The experiments dem-
onstrate the feasibility of antisense ODN application for treat-
ment of hypertension and we are currently developing methods of
vector delivery for long-term inhibition and prevention of hyper-
tension.
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